Use of Ampicillin/Sulbactam and Sultamicillin in Pediatric Infections: A Re-Evaluation

Journal of International Medical Research - Tập 29 Số 4 - Trang 257-269 - 2001
AS Dajani1
1Department of Pediatrics, Wayne State University School of Medicine; and Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, MI, USA

Tóm tắt

Ampicillin/sulbactam is an effective solution to the emergence of β-lactamase-mediated resistance among common pediatric pathogens, and is a widely recognized treatment option for a variety of pediatric infections. Recent antimicrobial surveillance data confirm the continued susceptibility of many Gram-positive and Gram-negative aerobes and anaerobes to ampicillin/sulbactam. Pharmacokinetic studies have demonstrated high drug concentrations at a variety of infection sites, including cerebrospinal fluid and bone. Furthermore, clinical studies have shown that ampicillin/sulbactam, administered intravenously, intramuscularly or orally (as the mutual prodrug sultamicillin), is clinically and bacteriologically effective against upper and lower respiratory tract infections, urinary tract infections, skin, bone and soft-tissue infections, and meningitis, and provides effective surgical prophylaxis. Sultamicillin has an excellent tolerability profile, which is associated with a low rate of treatment discontinuation. Accordingly, ampicillin/sulbactam and sultamicillin should be considered first-choice options for the management of a variety of pediatric infections.

Từ khóa


Tài liệu tham khảo

10.1097/00006454-199803001-00002

10.1097/00006454-199803001-00003

10.2165/00003495-198800357-00009

10.3928/0090-4481-19930301-10

10.1097/00006454-199812000-00028

10.1086/501755

10.1179/joc.1999.11.Supplement-2.5

10.1016/S0011-393X(05)80192-4

10.1093/clinids/24.3.494

10.1016/S0924-8579(99)00085-0

10.2165/00003495-198733060-00003

10.1016/S0924-8579(99)00086-2

10.1016/0732-8893(94)90121-X

10.1016/0732-8893(95)00018-6

10.1016/0732-8893(93)90110-S

10.1093/clinids/8.Supplement_5.503

10.1128/AAC.31.11.1703

10.1093/clinids/8.Supplement_5.S512

10.1128/AAC.43.5.1225

10.1093/clinids/8.Supplement_5.S518

Komissarov IA, 1978, Vestn Khir, 120, 97

10.1093/jac/15.3.345

Lode H, 1989, APMIS Suppl, 5, 17

10.1007/BF01739028

Voelker MS, 1985, Curr Therapeutic Res, 38, 738

10.1097/00006454-199803001-00004

Huang LM, 1989, Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih, 30, 87

10.1016/0732-8893(89)90133-8

Scholz H, 1986, Zac A Antimikrob Antineoplast Chemother, 4, 89

10.1016/S0924-8579(96)80007-0

Alpuche-Aranda C, 1992, Rev Espan Quimioterapia, 5, 65

10.1016/0732-8893(89)90134-X

Mbonda E, 1992, Acta Therapeutica, 18, 301

Biolcati AH, 1992, J Int Med Res, 20

10.1097/00006454-199301000-00007

10.1093/jac/14.3.261

10.1093/clinids/8.Supplement_5.S617

Daniscovicova-Nogeova A, 1999, Antiinfect Drugs Chemother, 16, 219

Solbiati M, 1988, Chemioterapia, 7, 393

Cichocka E, 1993, Pediatr Pol, 68, 41

10.1001/archsurg.1992.01420010097015

10.1097/00006454-199803001-00005

10.1093/clinids/8.Supplement_5.S634

Dell'Agnola CA, 1992, Acta Urologica Italiana, 6, 445

10.2165/00003495-198800357-00017

10.1093/clinids/8.Supplement_5.S620

Kanra G, 1993, Turk J Pediatr, 35, 87

10.1097/00006454-198909000-00008

10.1128/AAC.31.4.663

10.1093/clinids/8.Supplement_5.S639

10.1093/clinids/8.Supplement_5.S644

10.1016/S0924-8579(96)00359-7

Thông tin
Thông tin xuất bản

Journal of International Medical Research

Tập 29 Số 4

257-269

Thông tin tác giả